Market Overview

UPDATE: Oppenheimer Maintains Idenix Pharmaceuticals at Perform Following Clinical Hold on IDX19368

Related IDIX
Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline
Stocks Poised to Slip from Record Highs (Fox Business)

Oppenheimer reiterated its Perform rating on Idenix Pharmaceuticals (NASDAQ: IDIX) as the company's second nucleotide is put on clinical hold.

Oppenheimer commented, "As in the case of IDX184, the FDA appears to have CV concerns regarding '368, given the significant safety issues seen with BMY's nuc BMS-986094. Although '368 has yet to even produce clinical safety data, the compound has been revealed to be a guanosine analog like '184/'094 and this is likely the rationale for the FDA's actions. With '368 and '184 under FDA investigation, the viability of both compounds is questionable. NS5a inhibitor IDX719 remains IDIX's only other promising candidate; however, it is in early ph.I development."

Idenix Pharmaceuticals closed at $6.01 on Friday.

Posted-In: OppenheimerAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (IDIX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters